Patents by Inventor Stephen J. Blakemore

Stephen J. Blakemore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING CANCER
    Publication number: 20220387611
    Abstract: The present invention relates to a method of treating cancer in a subject.
    Type: Application
    Filed: October 16, 2020
    Publication date: December 8, 2022
    Inventors: Gavin BENNETT, Stephen J. BLAKEMORE, Tara GELB
  • Biomarkers of response to NAE inhibitors
    Patent number: 10953013
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: March 23, 2021
    Assignees: Millennium Pharmaceuticals, Inc., The General Hospital Corporation
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • Biomarkers and methods to predict response to inhibitors and uses thereof
    Patent number: 10662477
    Abstract: Disclosed herein are markers associated with sensitivity to treatment with therapeutic agents. Methods to identify markers for predicting outcome to treatment with a therapeutic agent are disclosed as well as methods to predict outcome of treatment using markers. Compositions and methods are provided to predict response to NAE inhibition or EGFR inhibition treatment.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: May 26, 2020
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, Hyunjin Shin, William L. Trepicchio
  • METHODS OF TREATMENT OF CANCER
    Publication number: 20180117069
    Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of NF?B, as measured by a H-score of the patients tumor sample using a NF?B p65 IHC assay. The invention also provides a method of determining whether to treat a patient with a proteasome inhibitor based on the level of NF?B p65 in the patient's tumor sample.
    Type: Application
    Filed: June 6, 2017
    Publication date: May 3, 2018
    Inventors: Stephen J. Blakemore, Alessandra M. Di Bacco, George J. Mulligan
  • Biomarkers of response to NAE inhibitors
    Patent number: 9827246
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 28, 2017
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • METHOD OF TREATMENT OF NASOPHARYNGEAL CANCER
    Publication number: 20170157155
    Abstract: The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a “NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (/) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample.
    Type: Application
    Filed: November 22, 2016
    Publication date: June 8, 2017
    Inventors: Stephen J. Blakemore, Alessandra M. Di Bacco, George J. Mulligan
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20170105995
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: June 3, 2016
    Publication date: April 20, 2017
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Lightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • METHODS OF TREATMENT OF CANCER
    Publication number: 20160008382
    Abstract: The present invention provides a method of treating cancer with a proteasome inhibitor. The invention also provides a method of treating a patient with cancer based on elevated expression levels of NF?B, as measured by a H-score of the patients tumor sample using a NF?B p65 IHC assay. The invention also provides a method of determining whether to treat a patient with a proteasome inhibitor based on the level of NF?B p65 in the patient's tumor sample.
    Type: Application
    Filed: January 23, 2013
    Publication date: January 14, 2016
    Inventors: Stephen J. BLAKEMORE, Alessandra M. DI BACCO, George J. MULLIGAN
  • BIOMARKERS AND METHODS TO PREDICT RESPONSE TO INHIBITORS AND USES THEREOF
    Publication number: 20150240315
    Abstract: Disclosed herein are markers associated with sensitivity to treatment with therapeutic agents. Methods to identify markers for predicting outcome to treatment with a therapeutic agent are disclosed as well as methods to predict outcome of treatment using markers. Compositions and methods are provided to predict response to NAE inhibition or EGFR inhibition treatment.
    Type: Application
    Filed: October 1, 2013
    Publication date: August 27, 2015
    Inventors: Stephen J. Blakemore, Bin Li, Hyunjin Shin, William L. Trepicchio
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20150119410
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 30, 2015
    Applicants: Millennium Pharmaceuticals, Inc, Massachusetts General Hospital
    Inventors: Cyril H. Benes, Stephen J. Blakemore, Jonathan L. Blank, Eric S. Llightcap, George J. Mulligan, Matthew C. Schu, Peter G. Smith, Jeffrey E. Settleman
  • BIOMARKERS OF RESPONSE TO NAE INHIBITORS
    Publication number: 20150105411
    Abstract: Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers associated with the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.
    Type: Application
    Filed: October 26, 2012
    Publication date: April 16, 2015
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Stephen J. Blakemore, Bin Li, George J. Mulligan, Matthew C. Schu, Peter G. Smith
  • METHOD OF TREATMENT OF NASOPHARYNGEAL CANCER
    Publication number: 20140357596
    Abstract: The present invention provides a method of treating nasopharyngeal cancer with a proteasome inhibitor of formula (7). The invention also provides a method of treating a patient with nasopharyngeal cancer based on elevated expression levels of NFkB, as measured by a H-score of the patient's nasopharyngeal cancer tumor sample using a “NFkB p65 IHC assay. The invention also provides a method of determining whether to treat a patient with the compound of formula (I) based on the level of NFkB p65 in the patient's nasopharyngeal cancer tumor sample.
    Type: Application
    Filed: January 23, 2013
    Publication date: December 4, 2014
    Inventors: Stephen J. Blakemore, Alessandra M. Di Bacco, George J. Mullingan